Effects of Peanut Consumption on Adults With Metabolic Associated Fatty Liver Disease
Impacts of Peanut Intake on Hepatic Markers and Gut Microbiota in Adults With MASLD
2 other identifiers
interventional
125
1 country
1
Brief Summary
The aim of this randomized interventional trial is to understand the effects of peanut consumption on patients with metabolic associated fatty liver. The main goal is to investigate if patients who consume peanuts have improved liver marker tests as well as metabolic profile. We will also investigate how peanuts alter the gut microbes and liver fat content in patients with metabolic associated fatty liver.
- Participants will be randomized into intervention (peanut consumption for 12 weeks) and control (regular diet) arm.
- Stool sample and blood (for biomarkers) collection across both arms at baseline and post-intervention
- Daily log to be completed for tracking peanut consumption
- 2-day Dietary recall at baseline, during Week 6 and Week 12
- Poat intervention Fibro scans for participants with baseline scans available
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Jun 2026
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
June 9, 2026
CompletedStudy Start
First participant enrolled
June 9, 2026
CompletedFirst Posted
Study publicly available on registry
June 12, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 6, 2028
ExpectedStudy Completion
Last participant's last visit for all outcomes
June 9, 2028
June 12, 2026
June 1, 2026
1.8 years
June 9, 2026
June 9, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Hepatic Markers
Changes in hepatic markers such as ALT, ASP, ALP will be evaluated through blood tests at baseline and post-intervention
Baseline to post-intervention (12 weeks)
Secondary Outcomes (3)
Metabolic Profile
Baseline to post-intervention (12 weeks)
Gut microbiota composition
Baseline to post-intervention (12 weeks)
Intrahepatic fat content
Baseline to post-intervention (12 weeks)
Study Arms (2)
Peanut
EXPERIMENTALMASLD patients will consume 50 gm of peanut daily for 12 weeks
Control
NO INTERVENTIONRegular diet
Interventions
Eligibility Criteria
You may qualify if:
- years
- do not consume peanut/peanut butter/treenut/seeds \> /week
- at least one encounter-related (stage F0/F1) MASLD diagnosis (K76.0)
- Able to understand, speak, and read English
- Mentally competent to consent
You may not qualify if:
- Food allergy to peanuts or peanut-containing products
- With alcohol use disorder (AUDIT screening)
- Leukemia
- Lymphoma
- Other types of cancer
- Heart or cardiovascular diseases (such as heart attack, stroke, heart failure)
- Kidney diseases (such as chronic kidney disease, kidney transplant, renal insufficiency such as renal failure requiring dialysis)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Henry Ford Health System
Detroit, Michigan, 48202, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- SUPPORTIVE CARE
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Assistant Scientist
Study Record Dates
First Submitted
June 9, 2026
First Posted
June 12, 2026
Study Start
June 9, 2026
Primary Completion (Estimated)
April 6, 2028
Study Completion (Estimated)
June 9, 2028
Last Updated
June 12, 2026
Record last verified: 2026-06